In an attempt to combat bacterial infections, Locus Biosciences is developing bacteriophage therapies that deliver CRISPR-Cas3 machinery directly to specific, targeted pathogens to obliterate them. Locus CEO Paul Garofolo discusses the company's technology and recent updates with The ScienceBoard.net. Discuss
Similar safety and immunogenicity profiles were observed in adults and older adults who received the Oxford/AstraZeneca SARS-CoV-2 vaccine candidate, ChAdOx1 nCoV-19, according to data from the phase II clinical trial. The findings were published in the Lancet on November 18. Discuss
Pfizer and BioNTech have passed another milestone in their effort to deliver a vaccine for the SARS-CoV-2 virus. The companies on November 18 reported that their BNT162b2 vaccine candidate has met safety milestones and that they plan to apply for an emergency use authorization (EUA) from the U.S. Food and Drug Administration for the product in the coming days. Discuss
Researchers have shed light on the "known unknowns" of preexisting and acquired T-cell responses in relation to SARS-CoV-2 infection. In a perspective piece, published in Science Immunology on November 18, scientists from Karolinska Institutet in Sweden discuss the role and durability of T-cell responses in COVID-19. Discuss
A new virtual reality tool offers scientists a chance to "step inside" the SARS-CoV-2 virus's main enzyme responsible for replication and manipulate it in atomic detail to find ways to shut it down. The technology could enable researchers in different locations to collaborate on drug development within a virtual environment. Discuss
A COVID-19 vaccine under development by Moderna had 94.5% efficacy in a phase III clinical trial, according to an independent data safety monitoring board that notified the company of the results. The news builds on positive sentiment that a solution to the COVID-19 pandemic could be around the corner. Discuss
The likelihood of SARS-CoV-2 developing resistance to COVID-19 vaccines currently under development can be determined using repurposed blood and nasal test samples that are already being collected as part of clinical trials, according to Pennsylvania State University researchers. The perspective piece was published in PLOS Biology on November 9. Discuss
Vaccines are considered one of the most effective public health measures preventing diseases in the modern world. They could also be very profitable endeavors, according to a new report from Kalorama Information, which estimates the market for COVID-19 vaccines could be as high as $27 billion. Discuss
Researchers have unearthed how the SARS-CoV-2 virus employs genomic "origami" to infect and replicate inside host cells, a discovery that may hold the key to developing novel antiviral drugs that target specific areas of the virus's genomic structure. The findings were published on November 5 in Molecular Cell. Discuss
Gene therapies offer great benefits to patients but could strain healthcare budgets and exacerbate existing treatment inequities in Canada, according to an expert panel that was commissioned to write a report by the Council of Canadian Academies. Discuss
Conferences
2020 AACC Annual Scientific Meeting & Clinical Lab Expo
December 13-17
Online
December 13-17
Online
Society for Laboratory Automation and Screening (SLAS) 2021
January 23-27, 2021
Online
January 23-27, 2021
Online
Festival of Genomics & Biodata
January 28-29, 2021
London, Greater London United Kingdom
January 28-29, 2021
London, Greater London United Kingdom
4th Annual Cell & Gene Therapy Innovation Leaders Summit 2021 Visualising The Future
February 1-3, 2021
Berlin, Berlin Germany
February 1-3, 2021
Berlin, Berlin Germany
Lab of the Future USA
May 11-12, 2021
Boston, Massachusetts United States
May 11-12, 2021
Boston, Massachusetts United States
Science Briefs
Insights
Exclusive content for Science Advisory Board members on trends and outcomes that are influencing the future of scientific research.
Communities
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Rewards
Earn points for contributing to research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Connect
